Reboot biomedical R&amp;D in the global public interest

Swaminathan, Soumya; Pécoul, Bernard; Abdullah, Hisham Wan; Christou, Christos; Gray, Glenda; IJsselmuiden, Carel; Kiény, Marie Paule; Mazzucato, Mariana; Messling, Véronika von; Ogutu, Bernhards; Reeder, John C.; Røttingen, John-Arne; Swarup, R.; Tanner, Marcel; Lima, Nísia Trindade; Childs, Michelle; Harris, Alex H. S.; Torreele, Els; Moon, Suerie

doi:10.1038/d41586-022-00324-y

Cited by 32 publications

(27 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to his work as a distinguished researcher and teacher, Tanner was involved in several product development partnerships (PDPs), bringing together partners from research, academia, and the private sector. He was a founding member of the Medicines for Malaria Venture (MMV) and chaired the Drugs for Neglected Diseases initiative (DNDi) and the Foundation for Innovative New Diagnostics (FIND), all based in Geneva [ 30 , 31 ].…”

Section: Discussionmentioning

confidence: 99%

No Roots, No Fruits: Marcel Tanner’s Scholarly Contribution, Achievements in Capacity Building, and Impact in Global Health

2022

View full text Add to dashboard Cite

On 1 October 2022, Marcel Tanner celebrated his 70th birthday with his family and friends on the River Rhein in Basel. Trained in epidemiology (Ph.D.) and public health (MPH), Tanner devoted his entire working life to research, teaching, and capacity building. Indeed, he built up productive partnerships, fostered multinational consortia, served on numerous scientific and strategic advisory boards, and contributed measurably to improving people’s health and well-being. We systematically searched the Web of Science Core Collection to identify Tanner’s scholarly contribution and pursued an in-depth analysis of his scientific oeuvre including the main areas of research, pathogens, diseases, and health systems, and the geographical foci of his scholarly activities. Additionally, we examined Tanner’s impact on personal and institutional capacity building in the arena of global health. We also invited a handful of colleagues to describe their experiences while working with Marcel Tanner. What transpires is a considerable breadth and depth of peer-reviewed publications in tropical medicine; epidemiology, environmental, and occupational health; parasitology; and infectious diseases. More than a third of the 622 peer-reviewed articles, the first piece published in 1978, focused on various aspects of the protozoan parasite Plasmodium and the disease it causes: malaria. Tanner trained, taught, and inspired generations of students, scientists, and practitioners all over the world. His unique ability to bring people and institutions together to work in partnership is at the heart of an impactful career in global health.

show abstract

Section: Discussionmentioning

confidence: 99%

No Roots, No Fruits: Marcel Tanner’s Scholarly Contribution, Achievements in Capacity Building, and Impact in Global Health

2022

View full text Add to dashboard Cite

show abstract

“…Critical among their recommendations was the need for "a change of rules and incentives", particularly around intellectual property, "to secure the rapid, open sharing of inputs, processes and outputs." (Swaminathan et al, 2022).…”

mentioning

confidence: 99%

Overcoming Market Failures in Pandemic Drug Discovery Through Open Science: A Canadian Solution

Gold

Edwards

2022

Front. Drug. Discov.

View full text Add to dashboard Cite

Among the lessons learned from the COVID-19 pandemic is the need to develop antiviral drugs poised to treat the next pandemic. Unfortunately, traditional drug development economic models, centered principally on patents, are ineffective to induce private sector investment due to unpredictable timing and cause of the next pandemic. As a result, illustrated by the COVID-19 pandemic, it is the public and philanthropic sectors sectors that overwhelmingly fund the development of innovative vaccines and therapies. To meet the need for proactive antiviral medicines in advance of the next pandemic, new models of drug development are needed. Open science partnerships (OSPs) show promise in this regard. Rather than rely principally on patents and private investment, OSPs combine a variety of academic, philanthropic, governmental, and private sector incentives to share knowledge and develop and test antiviral drugs. Private sector investments are, within an OSP, not only leveraged against investments by other actors, but predicated on gaining regulatory data exclusivity, a known and secure form of commercial advantage. Building on domestic expertise in OSPs, Canadian leaders created the Viral Interruption Medicines Initiative, a not-for-profit OSP, to develop pandemic ready-antivirals and address other areas of market failure.

show abstract

“…Technology sharing models are critical to promoting technological catch-up based on public interest. 3 A good example is the World Health Organization’s (WHO) COVID-19 Technology Access Pool, an initiative that aims to expand equitable access to COVID-19 health products, providing a global platform for developers to share knowledge, intellectual property and data. In November 2021, the technology access pool and the Medicines Patent Pool announced a licence with the Spanish National Research Council for a COVID-19 serological antibody technology.…”

mentioning

confidence: 99%